Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-04-29
DOI
10.1111/cas.14032
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
- (2018) Laurent Mhanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
- (2018) Jaemin Jo et al. YONSEI MEDICAL JOURNAL
- Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
- (2018) Geeta Sharma et al. Cancers
- Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)
- (2017) Siow Ming Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation
- (2017) Xi Ding et al. Cancer Medicine
- Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer
- (2016) Thomas E. Stinchcombe et al. Clinical Lung Cancer
- The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
- (2015) Yaxiong Zhang et al. MEDICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
- (2014) Lei Wang et al. BMC CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
- (2013) Helen Vassalou et al. LUNG CANCER
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed
- (2012) Daniel C. Christoph et al. Journal of Thoracic Oncology
- Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis
- (2012) Hai-Long Zhang et al. LUNG CANCER
- ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
- (2010) A. C. Vilmar et al. ANNALS OF ONCOLOGY
- The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
- (2010) Lars Petter Jordheim et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now